Jyong Biotech Ltd.

MENSdata completeness 75%3 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'interestExpense'; no data for concept 'incomeTaxExpense'

i. The business — what you’d actually own

Figure	FY 2023	FY 2024	FY 2025
Revenue	—	—	—
Net income	−$4.4M¹	−$3.02M¹	−$4.67M¹
Operating cash flow	−$2.6M²	−$3.62M²	−$3.04M²
Capital expenditure	—	—	—
Free cash flow (derived)	—	—	—
Total debt	—	—	$17.5M³
Cash & equivalents	$1.74M⁴	$101,000⁴	$1.18M⁴
Diluted shares	71.6M	71.6M	73.0M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$3.41

your share of equity

Profit it earned you last year

−$0.64

Free cash flow it threw off

—

Debt you’d be carrying

$2.39

10 shares is a claim on −$3.41 of net worth that earned you −$0.64 last year, against $2.39 of debt.

iii. Is this a good business?

Moat signal · return on equity

— avg · 3y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

+2% shares · 3y

Share count is up 2% over 3 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts